Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE) [PDF]
Clinical and Translational Allergy, 2022 Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli +13 more
doaj +2 more sources
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study [PDF]
Respiratory Research, 2023 Background The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects.
Alessandra Vultaggio +22 more
doaj +2 more sources
Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study [PDF]
BMC Pulmonary MedicinePurpose This real-world study compared the efficacy and the proportion of patients attaining the criteria constituting clinical remission at 12 months between mepolizumab and benralizumab in patients with severe eosinophilic asthma.
Wei-Chun Huang +6 more
doaj +2 more sources
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis [PDF]
Frontiers in Allergy, 2022 BackgroundSevere eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation.
Maria D'Amato +27 more
doaj +6 more sources
Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience [PDF]
Annals of MedicineObjectives Benralizumab emerged as a promising treatment option for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the long-term effectiveness and safety of benralizumab in patients with severe asthma and relapsing-refractory ...
Federica Davanzo +10 more
doaj +2 more sources
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. [PDF]
Arthritis RheumatolOBJECTIVE: The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Nair PK +14 more
europepmc +3 more sources
Frontiers in Pharmacology, 2022 Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga +7 more
doaj +1 more source
Фармакоэкономика, 2022 Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe ...
M. V. Zhuravleva +3 more
doaj +1 more source
Biomolecules, 2023 Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine.
Yuuki Sandhu +17 more
doaj +1 more source
Clinical Remission in Severe T2-High Asthma in Real Life After Anti-IgE, Anti-IL-5 and Anti-IL5R: A Potential Role for CRP as a Biomarker. [PDF]
Clin Transl AllergyABSTRACT Background Biotherapies have transformed the management of severe asthma (SA), shifting treatment goals from disease control toward achieving clinical remission. This study aimed to evaluate the effectiveness of biotherapies in inducing remission in severe asthma and to identify baseline patient characteristics that could predict remission ...
Vervier J +12 more
europepmc +2 more sources